Products Affected - Description
Bumetanide tablets, Mylan Institutional
0.5 mg unit-dose tablets, 100 count (NDC 51079-0891-20) - discontinued
1 mg unit-dose tablets, 25 count (NDC 51079-0892-19) - discontinued
1 mg unit-dose tablets, 100 count (NDC 51079-0892-20) - discontinued
2 mg unit-dose tablets, 100 count (NDC 51079-0893-20) - discontinued
Bumetanide tablets, Sandoz
0.5 mg tablets, 100 count (NDC 00185-0128-01)
0.5 mg tablets, 500 count (NDC 00185-0128-05)
1 mg tablets, 100 count (NDC 00185-0129-01)
1 mg tablets, 500 count (NDC 00185-0129-05)
2 mg tablets, 100 count (NDC 00185-0130-01)
2 mg tablets, 500 count (NDC 00185-0130-05)
Bumetanide tablets, Teva
1 mg tablets, 100 count (NDC 00093-4233-01)
1 mg tablets, 1000 count (NDC 00093-4233-10)
2 mg tablets, 100 count (NDC 00093-4234-01)
2 mg tablets, 1000 count (NDC 00093-4234-10)
Reason for the Shortage
- Mylan Institutional discontinued bumetanide tablets in March 2014.
- Sandoz cannot provide a reason for the shortage.
- Teva cannot provide a reason for the shortage.
Bumetanide tablets, Teva
0.5 mg tablets, 100 count (NDC 00093-4232-01)
Estimated Resupply Dates
- Sandoz has all bumetanide tablet presentations on back order and the company cannot estimate a release date.
- Teva has bumetanide 1 mg tablets in 100 and 1000 count and 2 mg tablets in 100 and 1000 count on back order and the company estimates a release date of late-July to early-August 2014.
June 30, 2014; June 4, 2014; April 30, 2014 March 5, 2014; January 27, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins